secwatch.observer — SEC 8-K summary
======================================

Issuer:     Sagimet Biosciences Inc. (SGMT)
CIK:        0001400118
Form:       8-K
Filed at:   2024-06-06T23:59:59+00:00
Accession:  0001104659-24-068817
Event type: other_material
Sentiment:  positive
Materiality: 0.85
Item codes: 5.07, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Sagimet reports positive FASCINATE-2 Phase 2b data; denifanstat meets primary endpoints in MASH
--------------------------------------------------------------------------------

- Primary endpoint: MASH resolution with ≥2-point NAS reduction without worsening fibrosis: 38% denifanstat vs 16% placebo (p=0.0035) in ITT.
- Fibrosis improvement ≥1 stage without worsening MASH: 30% vs 14% placebo (p=0.0199) in ITT; 49% vs 13% in F3 subgroup (p=0.0032).
- Fibrosis improvement ≥2 stages in mITT: 20% vs 2% placebo (p=0.0065); 34% vs 4% in F3 subgroup (p=0.0050).
- No treatment-related SAEs; most AEs mild/moderate. TEAE discontinuation 19.6% denifanstat vs 5.4% placebo.
- Company plans to initiate Phase 3 registrational program for denifanstat in MASH with fibrosis in H2 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1400118/000110465924068817/0001104659-24-068817-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1400118/000110465924068817/tm2416614d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-24-068817

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer